Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study
Digestive and Liver Disease · 2024-01 · 56 (1) · 77-82
DOI: 10.1016/j.dld.2023.07.011 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Digestive and Liver Disease, 2024-01. Verfasst von Davide Giuseppe Ribaldone und 41 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, University of Turin, Turin, Italy. Electronic address: davidegiuseppe.ribaldone@unito.it. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The administration of biological drugs in inflammatory bowel diseases (IBD) is increasingly moving from intravenous to subcutaneous formulations. AIMS: To evaluate the efficacy and safety of vedolizumab subcutaneous administration after switching from intravenous administration in ulcerative colitis (UC) patients in corticosteroid-free clinical remission. METHODS: An observational, multicentre, prospective study was conducted by the Italian Group for the study of IBD (IG-IBD). UC patients in clinical remission (pMAYO 8 months before the switch, and with at least 6 months of follow-up were included. Switch from intravenous to subcutaneous vedolizumab was defined as successful in patients not experiencing a disease flare (pMAYO ≥ 2) or needing oral steroids or stopping subcutaneous vedolizumab during the 6 months of follow-up after the switch. RESULTS: Overall, 168 patients were included. The switch was a success in 134 patients (79.8%). Vedolizumab retention rate was 88.7% at month six. C-reactive protein and faecal calprotectin values did not change after the switch (p = 0.07 and p = 0.28, respectively). Ten of the 19 patients who stopped subcutaneous formulation switched back to intravenous formulation recapturing clinical remission in 80%. Side effects were observed in 22 patients (13.1%). CONCLUSION: Effectiveness of switching from intravenous to subcutaneous vedolizumab formulation in UC patients in steroid-free clinical remission is confirmed in a real-world setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Sciences, University of Turin, Turin, Italy. Electronic address: davidegiuseppe.ribaldone@unito.it.
- CEAMD- IBD Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome 00168, Italy.
- IBD Unit - IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella, Verona, Italy.
- Division of Gastroenterology and Endoscopy, Fondazione IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo, Foggia, Italy.
- Gastroenterology, Department of Clinical Medicine and Surgery, School of Medicine Federico II of Naples, Italy.
- UOC Gastroenterologia Ospedale Veris delli Ponti, Scorrano, LE, Italy.
Zitieren
APA
Ribaldone, D. G., Parisio, L., Variola, A., Bossa, F., Castiglione, F., Marzo, M., Piazza, N., Aratari, A., Savarino, E. V., Bodini, G., Mastronardi, M., Micheli, F., Mazzuoli, S., Ascolani, M., Viganò, C., Cappello, M., Bezzio, C., Ciccocioppo, R., Scardino, G., …, & Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) (2024). Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study. Digestive and Liver Disease, 56(1), 77-82. https://doi.org/10.1016/j.dld.2023.07.011
Vancouver
Ribaldone DG, Parisio L, Variola A, Bossa F, Castiglione F, Marzo M, et al. Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study. Digestive and Liver Disease. 2024;56(1):77-82. doi:10.1016/j.dld.2023.07.011
BibTeX
@article{Ribaldone2024,
author = {Ribaldone, Davide Giuseppe and Parisio, Laura and Variola, Angela and Bossa, Fabrizio and Castiglione, Fabiana and Marzo, Manuela and Piazza, Nicole and Aratari, Annalisa and Savarino, Edoardo Vincenzo and Bodini, Giorgia and Mastronardi, Mauro and Micheli, Federica and Mazzuoli, Silvia and Ascolani, Marta and Viganò, Chiara and Cappello, Maria and Bezzio, Cristina and Ciccocioppo, Rachele and Scardino, Giulia and Sarli, Ennio and Pugliese, Daniela and Scaldaferri, Franco and Napolitano, Daniele and Todeschini, Alessia and Geccherle, Andrea and Colaci, Nicoletta and Guerra, Maria and Annese, Monica and Testa, Anna and Caiazzo, Anna and Conforti, Francesco Simone and Festa, Stefano and Lorenzon, Greta and Marra, Antonella and Magiotta, Ambra and Baccini, Flavia and Amato, Arnaldo and Poshnjari, Anxhela and Vernero, Marta and Caprioli, Flavio and Caviglia, Gian Paolo and Italian Group for the study of Inflammatory Bowel Disease (IG-IBD), Italian Group for the study of Inflammatory Bowel Disease (IG-IBD)},
title = {Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study},
journal = {Digestive and Liver Disease},
year = {2024},
volume = {56},
number = {1},
pages = {77--82},
doi = {10.1016/j.dld.2023.07.011}
}
EUVIMED